Konakion MM is indicated as an antidote to anticoagulant drugs of the coumarin type in the treatment of haemorrhage or threatened haemorrhage, associated with a low blood level of prothrombin or factor VII.
Konakion MM Paediatric/Phytomenadione 2 mg/0.2 ml is indicated for the prophylaxis and treatment of vitamin K deficiency bleeding (VKDB) in neonates and infants. Konakion MM Paediatric/Phytomenadione 2 mg/0.2 ml can be used, following specialist advice from a haematologist, as an antidote to anticoagulant drugs of the coumarin type in infants and children. For use as an antidote to anticoagulant drugs of the coumarin type in adolescents and adults, refer to Konakion MM Ampoules 10 mg/ml solution for injection or Phytomenadione 10 mg/1 ml solution for injection.
The FDA has approved the 32 mm and 38 mm lengths for the Promus Element Plus Everolimus-Eluting Platinum Chromium Coronary...
Merrimack Pharmaceuticals has announced detailed results from NAPOLI-1, a large, randomized, three-arm Phase III study of MM 398 (nanoliposomal encapsulated...
The pivotal Phase III trial (known as ICARIA-MM) of SAR 650984 (isatuximab), from Sanofi, in patients with relapsed/refractory multiple myeloma...
Celgene International S�rl, announced updated results of its pivotal phase III FIRST (MM-020/IFM 07-01) trial, comparing continuous Revlimid (lenalidomide) plus...
Results of a Phase II study of 124 patients with advanced Oesophago-Gastric Cancer who had failed one prior chemotherapy regimen...
Baxter International Inc.and Merrimack Pharmaceuticals, Inc.jointly announced that Baxter has submitted a marketing authorization application (MAA) to the European Medicines...
Results from a Phase II study of PEP02, also known as MM 398 (nanoliposomal irinotecan), from Merrimack Pharmaceuticals, as second-line...
Multiple myeloma (MM) is the second most common blood cancer following non-Hodgkin's lymphoma. While the treatments for MM have improved over the past decade, for the most part, it remains an incurable disease.